John Reneau
This phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in treating patients with cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with third-party natural killer cells, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Mogamulizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving third-party natural killer cells in combination with mogamulizumab may kill more cancer cells.
PRIMARY OBJECTIVE: I. To determine safety, tolerability, and determine the maximum tolerated dose (MTD) of IL-21 expanded, off the shelf, third-party natural killer (NK) cells and mogamulizumab in patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL) and adult T-cell leukemia/lymphoma (ATLL). SECONDARY OBJECTIVES: I. To determine the overall response rate (ORR), progression free survival (PFS) and overall survival (OS) in same patient population treated with IL-21 expanded, off the shelf, third-party NK cells and mogamulizumab. II. To determine impact of treatment on quality o…
Inclusion Criteria: * Able to understand and voluntarily sign an informed consent form * Age \>= 18 years at the time of signing the informed consent form * Able to adhere to the study visit schedule and other protocol requirements * Biopsy-proven, measurable, stage IB-IVB relapsed or refractory cutaneous T-cell lymphoma after 1 prior line of systemic therapy * Note: extracorporeal photopheresis will be considered a systemic therapy for this study * Patients with large cell transformation of cutaneous T cell lymphoma are eligible * Patients with adult T-cell leukemia/lymphoma (ATLL) of any…
Given IV
Given IV
Given IV
Given via infusion
Ancillary studies
Ancillary studies
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.